MapLight Therapeutics CEO sells shares for taxes

MapLight Therapeutics, Inc. CEO and director Christopher A. Kroeger reported sales totaling 147,639 shares of Voting Common Stock between July 15 and 17, 2026.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. CEO and director Christopher A. Kroeger reported sales totaling 147,639 shares of Voting Common Stock between July 15 and 17, 2026. Footnotes state these were mandated sell‑to‑cover transactions to satisfy statutory tax withholding on vested restricted stock units, rather than discretionary sales. After these transactions, he holds 1,246,455 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, over which he has voting and dispositive power.

Insider Trade Summary

Net Seller: 147,639 shares

Net Sell 8 txns

Insider Kroeger Christopher A.

Role Chief Executive Officer

Sold 147,639 shs ($5.44M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock F1, F6	16,779	$37.90	$636K
Sale	Voting Common Stock F1, F4	40,899	$36.46	$1.49M
Sale	Voting Common Stock F1, F5	28,091	$37.26	$1.05M
Sale	Voting Common Stock F1	92	$37.96	$3K
Sale	Voting Common Stock F1, F2	18,950	$36.00	$682K
Sale	Voting Common Stock F1, F3	42,738	$36.99	$1.58M
Sale	Voting Common Stock F1	90	$37.54	$3K
holding	Voting Common Stock F7	--	--	--

Holdings After Transaction: Voting Common Stock — 1,246,455 shares (Direct); Voting Common Stock — 101,190 shares (Indirect, See footnote)

Footnotes (7)

1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

Key Figures

Shares sold for tax withholding: 147,639 shares Direct holdings after transactions: 1,246,455 shares Indirect trust holdings: 101,190 shares +2 more

5 metrics

Shares sold for tax withholding 147,639 shares Aggregate mandated sell-to-cover sales on July 15–17, 2026

Direct holdings after transactions 1,246,455 shares Voting Common Stock held directly by Christopher A. Kroeger after July 17, 2026

Indirect trust holdings 101,190 shares Voting Common Stock held indirectly via C&M Kroeger Nominee Trust

Weighted avg sale price (July 17, 2026) $37.90 per share Weighted-average price for 16,779-share sell-to-cover transaction

Price range for July 15, 2026 sale $35.5338–$36.5273 per share Execution price range for the 18,950-share sale noted in a footnote

Key Terms

restricted stock units, sell to cover, weighted average price, statutory tax withholding obligations, +1 more

5 terms

restricted stock units financial

"in connection with the vesting of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"to be funded by a sell to cover transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

statutory tax withholding obligations financial

"required to be sold to cover the statutory tax withholding obligations"

voting and dispositive power financial

"of which the Reporting Person is co-trustee ... and has voting and dispositive power."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did MapLight Therapeutics (MPLT) disclose in this Form 4?

MapLight Therapeutics reported that CEO Christopher A. Kroeger sold 147,639 shares of Voting Common Stock from July 15–17, 2026. Footnotes explain these were mandated sell‑to‑cover transactions for tax withholding on vested restricted stock units, not discretionary trades.

How many MPLT shares did Kroeger sell and for what purpose?

Kroeger sold a total of 147,639 MPLT shares. According to footnotes, these sales represent shares required to be sold to cover statutory tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans.

What prices were involved in the recent MPLT insider share sales?

One reported transaction on July 17, 2026 used a weighted‑average price of $37.90 per share for 16,779 shares. Other trades used weighted‑average prices with execution ranges, including from $35.5338 to $36.5273 per share for an 18,950‑share sale.

How many MapLight Therapeutics (MPLT) shares does Kroeger own after these transactions?

Following the reported sell‑to‑cover transactions, Kroeger directly owns 1,246,455 MPLT Voting Common Stock shares. He also has indirect ownership of 101,190 shares held through the C&M Kroeger Nominee Trust, where he shares voting and dispositive power with his spouse.

What is the nature of Kroeger’s indirect MPLT share ownership?

The filing shows 101,190 MPLT shares held indirectly by the C&M Kroeger Nominee Trust. A footnote states Kroeger is co‑trustee with his spouse and has voting and dispositive power over these shares through the trust structure.

Were Kroeger’s MPLT share sales made under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5‑1 checkbox is not marked as plan transactions, and a data field indicates no 10b5‑1 plan was affirmed. The tax‑related footnote instead attributes the sales to mandated sell‑to‑cover activity for withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kroeger Christopher A.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	07/15/2026		S		18,950(1)	D	$36(2)	1,375,144	D
Voting Common Stock	07/15/2026		S		42,738(1)	D	$36.99(3)	1,332,406	D
Voting Common Stock	07/15/2026		S		90(1)	D	$37.54	1,332,316	D
Voting Common Stock	07/16/2026		S		40,899(1)	D	$36.46(4)	1,291,417	D
Voting Common Stock	07/16/2026		S		28,091(1)	D	$37.26(5)	1,263,326	D
Voting Common Stock	07/16/2026		S		92(1)	D	$37.96	1,263,234	D
Voting Common Stock	07/17/2026		S		16,779(1)	D	$37.9(6)	1,246,455	D
Voting Common Stock								101,190	I	See footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)